<?xml version="1.0" encoding="UTF-8"?>
<p id="p0555">
 <italic>Boswellia papyrifera</italic> (Del) Hochst olibanum
 <italic>, Chelidonium majus</italic> L, 
 <italic>Cymbopogen citratus, Cymbopogen nervatus</italic> inflorescences, 
 <italic>Cymbopogen proximus, Eucalyptus camaldulensis, Inula helenium</italic> L. subsp. 
 <italic>turcoracemosa, Khaya senegalensis, Micromeria juliana, Nigella sativa, Pinus brutia</italic> Ten, 
 <italic>Premna odorata, Rosmarinus officinalis</italic>, 
 <italic>Salvia aethiopis</italic> L, 
 <italic>Satureja aintabensis, Stachys sylvatica</italic> L, 
 <italic>Thymus sipthorpii</italic>, 
 <italic>Thymus vulgaris, Ulmus glabra</italic> Hudson, 
 <italic>Urtica dioica</italic> L, 
 <italic>Usnea barbata</italic> (L.) Mott and 
 <italic>Veratrum album</italic> L. are widely distributed in the MENA region and have been proven to contain potential agents against MTB. The bioactive compounds extracted from these plant materials have significant 
 <italic>in vitro</italic> activity. Specifically, their extracts have MICs of 1–50 µg/ml.
</p>
